Landscape of prurigo nodularis clinical trials

Prurigo nodularis (PN) is a chronic, pruritic dermatosis leading to debilitating itch and sleep disturbances. Since September 2022, dupilumab has been the only systemic medication for PN approved by the US Food and Drug Administration and the European Medicines Agency. Due to the recently expanding PN therapy clinical trials, we aimed to review the current clinical trial landscape for PN. "Prurigo nodularis" was searched on ClinicalTrials.gov. Data were collected for phase 1, 2, and 3 clinical trials investigating PN interventions. A total of 25 studies examined PN therapies, 17 of which were double-blind, randomized controlled trials, and 6 were open-label. Eleven therapies were or are currently under investigation. Other than the recently approved dupilumab, studies with potentially promising results included nemolizumab, vixarelimab, barzolvolimab, abrocitinib, povorcitinib, ruxolitinib, and nalbuphine. Therapies that will not undergo further studies include apremilast, serlopitant, and topical pimecrolimus. In summary, there are various potential efficacious medications for patients with PN on the horizon.